Erratum | Published:

Erratum: Can cancer clinical trials be fixed?

Nature Biotechnology volume 29, page 459 (2011) | Download Citation

Nat. Biotechnol. 29, 13–15 (2011); published online 10 January 2010; corrected after print 9 February 2011

In the version of the article originally published, it was stated that “Avastin was studied in combination with Taxol in all these trials, and compared to Taxol alone.” It should have read, “Avastin was studied in combination with chemotherapy.” In addition, it stated that the FDA had rescinded approval of Avastin for metastatic breast cancer. It should have read, the FDA “recommended removal of the breast cancer indication from the Avastin label...” The errors have been corrected in the HTML and PDF versions of the article.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt0511-459b

Authors

  1. Search for Malorye Allison in: